Zidesamtinib demonstrates 93% response rate in TKI-naive patients with advanced ROS1-positive NSCLC

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC